证券代码：阳普医疗 证券简称：300030 编号： 广州阳普医疗科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------------------|--------------------------------|----------------------------------------------------------------| | | | | | 投资者关系活动类别 | □ | 特定对象调研 □分析师会议 | | | □ 媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | √ 其他 | | | 参与单位名称及人员姓名 | 国信证券、铭基国际投资公司 | | | 时间 | 2016-2-29 | | | 地点 | 广州市阳普医疗大楼 | | | 上市公司接待人员姓名 | 倪桂英、刘璐 | | | 投资者关系活动主要内容介绍 | 1 、公司新产品准备情况 | | | | | 公司近两年能够上市的有血栓弹力图仪，预充式封管液，安全式正压留 | | | 置针，健康领域的排卵检测仪等。 | ...

证券代码：阳普医疗 证券简称：300030 广州阳普医疗科技股份有限公司投资者关系活动记录表 编号： | --- | --- | |----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | 投资者关系活动类别 | □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 √现场参观 □其他 | | 参与单位名称及人员姓名 | 方正证券 唐爱金、广东冠丰资产 杨欢、广州诚协投资管理 韦人元、上海友檀 投资管理 黄涵、安星资产 陈岳林、狄道投资 黄帅、国意投资 谢宇芊、金胜 ...

证券代码：300030 证券简称：阳普医疗 阳普医疗科技股份有限公司 投资者关系活动记录表 编号：20220429 | --- | --- | --- | |------------------------------|--------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | □特定对象调研 | □分析师会议 | | 投资者关系 | □媒体采访 | √业绩说明会 | | 活动类别 | □新闻发布会 | 路演活动 | | | □现场参观 | | | | 其他：投资者集体接待活动 | | | 参 与 单 位 名 称 及人员姓 ...

证券代码：300030 证券简称：阳普医疗 阳普医疗科技股份有限公司 投资者关系活动记录表 编号：20220922 | --- | --- | --- | |-------------------|------------------------------|---------------------------------------------------------------------------------| | | □特定对象调研 | □分析师会议 | | 投资者关系 | □媒体采访 | 业绩说明会 | | 活动类别 | □新闻发布会 | 路演活动 | | | □现场参观 | | | | √其他：投资者集体接待活动 | | | 参 与 单 位 名 称 | 线上参与" 2022 | 年广东辖区上市公司投资者网上集体接待日"活动的投资 | | 及人员姓名 | 者 | | | 时间 | 2022 年 9 月 22 | 日（周四） 15:50-16:50 | | 地点 | 全景网"投资者关系互动平台"（ | https://rs.p5w.net ） | | 上市公司 | 董事会秘书：余威先生 | | | ...

阳普医疗科技股份有限公司 2022 年第三季度报告 证券代码：300030 证券简称：阳普医疗 公告编号：2022-052 阳普医疗科技股份有限公司 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报 告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □是 否 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 177,119,317.52 | 2.13% | 529,552,805.76 | -10.19% | | 归属于上市公司股东的 | -21,836,610.48 | -60.81% | -57,801,791 ...

证券代码：300030 证券简称：阳普医疗 公告编号：2022-046 阳普医疗科技股份有限公司 关于参加广东辖区上市公司投资者网上集体接待日活动的公告 本公司及其董事会全体成员保证公告内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 为进一步加强与投资者的交流沟通，阳普医疗科技股份有限公司（以下简称 "公司"）将参加由广东证监局和广东上市公司协会共同举办的"2022 年广东 辖区上市公司投资者网上集体接待日"活动，现将有关事项公告如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供的网 上平台举行，投资者可以登录"全景•路演天下"网站（https://rs.p5w.net） 参与公司本次投资者网上集体接待日活动，活动时间为 2022 年 9 月 22 日（星期 四）15:50 至 16:50。 届时公司董事会秘书余威先生将通过网络在线交流形式，与投资者进行沟通 与交流。 欢迎广大投资者积极参与。 特此公告。 阳普医疗科技股份有限公司董事会 2022 年 9 月 21 日 ...

Financial Performance - The company reported a revenue of 300 million RMB for the first half of 2022, representing a year-on-year increase of 15%[16]. - The net profit attributable to shareholders was 50 million RMB, up 10% compared to the same period last year[16]. - The company's operating revenue for the reporting period was ¥352,433,488.24, a decrease of 15.33% compared to the same period last year[22]. - The net profit attributable to shareholders was -¥35,965,181.09, representing a decline of 140.05% year-on-year[22]. - The net cash flow from operating activities was ¥14,067,572.80, down 88.34% from the previous year[22]. - The company reported a significant decline in basic and diluted earnings per share, both at -¥0.12, down 141.38% from the previous year[22]. - The company's revenue for the reporting period was ¥352,433,488.24, a decrease of 15.33% compared to ¥416,242,340.16 in the same period last year, resulting in a decline of ¥67,999,851.92[89]. - The net profit for the first half of 2022 was a loss of CNY 35,057,334.29, compared to a profit of CNY 90,003,323.59 in the first half of 2021[198]. - The total equity of the company decreased to CNY 995,026,974.77 in the first half of 2022 from CNY 1,045,304,215.29 in the previous year, a decline of approximately 4.8%[196]. Research and Development - The company plans to invest 20 million RMB in R&D for new medical technologies and products in the upcoming year[16]. - The company invested CNY 20.3185 million in R&D during the reporting period, representing a year-on-year increase of 5.07%[76]. - The company has established five specialized teams and one public platform for R&D, focusing on various medical fields, including cardiovascular disease diagnosis and molecular diagnostics[76]. - The company has over 300 R&D professionals and aims to expand its IVD product scale and categories in precision medicine[52]. - The company is focusing on developing companion diagnostics to enhance personalized treatment efficiency[36]. - The company is focusing on the development of liquid biopsy technologies, which are expected to launch by the end of 2022[16]. - The company has signed a strategic cooperation agreement with the Guangdong Provincial Nurses Association to enhance resource sharing and collaboration[68]. Market Expansion and Strategy - The company has expanded its market presence in Southeast Asia, achieving a 30% growth in sales in that region[16]. - Future guidance estimates a revenue growth of 20% for the second half of 2022[16]. - The company is exploring potential acquisitions to enhance its product portfolio and market reach[16]. - The company focuses on expanding into lower-tier hospitals, leveraging partnerships with distributors and third-party medical testing laboratories[60]. - The company has established a marketing service network covering over 100 countries and regions, serving nearly 10,000 medical institutions[59]. - The company aims to become a leading provider of smart hospital solutions, integrating traditional HIS and EMR systems into a comprehensive clinical diagnosis platform[46]. Regulatory and Compliance - The company faces risks related to regulatory changes and market competition, with strategies in place to mitigate these risks[3]. - The company emphasizes a quality-first approach, aiming to provide safe and effective products, which enhances customer confidence and supports global competitiveness[70]. - The company has received the MDR certification on February 7, 2022, becoming one of the first global manufacturers to comply with EU MDR requirements[81]. - There were no administrative penalties related to environmental issues during the reporting period, indicating compliance with environmental regulations[133]. - The company is not listed as a key pollutant discharge unit by environmental protection authorities[133]. - The company has not faced any significant environmental compliance issues during the reporting period[133]. Financial Management - The company did not distribute cash dividends or issue bonus shares for the half-year period[124]. - The company implemented a stock incentive plan, granting 5.24 million restricted shares at a price of 6.83 yuan per share to 62 incentive recipients[125]. - The company canceled 2.62 million restricted shares due to unmet performance conditions for the second vesting period of the stock incentive plan[127]. - The company’s cash flow from financing activities increased by 104.73% to 265.14 million yuan due to increased bank borrowings[90]. - The company’s tax expenses decreased by 61.56% to ¥2,295,493.07 from ¥5,971,758.99, attributed to a reduction in taxable income[89]. Risks and Challenges - The company faces industry policy risks due to high regulatory scrutiny in the pharmaceutical sector, which may impact operations if strategies are not adjusted accordingly[115]. - The company acknowledges risks in new product and technology development, including potential delays or failures due to technical difficulties or market factors[116]. - The company faces talent and technology competition in the medical device industry, necessitating competitive compensation and intellectual property management to retain skilled personnel[119]. - The overseas export business remains a significant portion of total sales, with major clients in emerging markets like Colombia, Russia, Thailand, and Saudi Arabia, exposing the company to geopolitical and economic uncertainties[118]. Corporate Governance - The company has fulfilled all commitments made by actual controllers and shareholders during the reporting period[137]. - The company did not engage in any related party transactions during the reporting period[144]. - The company has no major contracts or leasing matters that significantly impacted profits[153]. - The company’s controlling shareholder and actual controller did not change during the reporting period[175]. - The company has no significant changes in shareholding structure or shareholder situation[163][168].

Financial Performance - The company reported a significant increase in revenue, with a year-on-year growth of 20% in 2021[14]. - The company's operating revenue for 2021 was approximately ¥799.83 million, a decrease of 12.99% compared to ¥919.23 million in 2020[18]. - The net profit attributable to shareholders was approximately ¥18.57 million, representing a significant decline of 88.57% from ¥162.52 million in 2020[18]. - The net profit after deducting non-recurring gains and losses was approximately ¥2.36 million, down 98.40% from ¥147.02 million in 2020[18]. - The total revenue for 2021 was 72.39 million, a decrease of 18.09 million compared to the previous year, resulting in a net profit of 54.30 million[187]. Market Expansion and Strategy - The company is focusing on expanding its market presence, particularly in the medical device sector, aiming for a 15% increase in market share by 2023[14]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach, targeting a 25% increase in operational capacity[14]. - The company aims to launch three new medical devices in the next fiscal year, contributing to an expected revenue increase of 30%[14]. - The company is committed to expanding its market presence and enhancing its product offerings in the healthcare sector[86]. - The company plans to enhance its technological capabilities through strategic partnerships and collaborations in the healthcare sector[189]. Research and Development - The company has invested in new product development, with a budget allocation of 10 million CNY for R&D in 2022[14]. - The company has established a strong R&D team and aims to enhance its position in the blood collection system market by developing standard tubes and specialized testing tubes[40]. - The company is developing a fully automated high-throughput PCR platform for tumor screening and diagnosis, which is unique in combining tumor and infectious disease testing[50]. - The company achieved a research and development investment of approximately ¥44.24 million, representing 5.53% of its operating revenue[125]. - The company is actively pursuing strategic partnerships and collaborations to enhance its service offerings and expand its operational capabilities[161]. Product Development and Innovation - The company is committed to ongoing research and development, as evidenced by its significant number of patents and continuous investment in new technologies[80]. - The company has developed a unique vacuum blood collection de-capping machine with biosafety features, which played a significant role during the COVID-19 pandemic[41]. - The company is advancing self-diagnosis for cardiovascular diseases from blood to urine, with a new product for monitoring aspirin usage currently in the registration process[43]. - The company has completed the development of a multifunctional general medical trolley, enhancing product variety and competitiveness[120]. - The company is developing a series of chemiluminescent assay reagents, which are in the small-scale testing phase and aim to enhance product competitiveness[123]. Financial Management and Governance - The company has implemented a three-year shareholder return plan for 2021-2023, aiming to enhance shareholder value[183]. - The company has revised multiple governance documents, including the articles of association and internal control systems, to improve corporate governance[183]. - The company emphasizes the importance of information disclosure, adhering to regulations and ensuring accurate and timely communication with investors[176]. - The management team has a strong background in healthcare and finance, which supports the company's strategic initiatives[192]. - The company has established a performance evaluation and incentive mechanism for directors and senior management, with a specific compensation management approach in place[178]. Operational Efficiency - The company is implementing new strategies to enhance supply chain efficiency, aiming for a 10% reduction in operational costs by 2023[14]. - The company saved over ¥100,000 annually through logistics process optimization, contributing to cost control efforts[100]. - The company is focusing on core business development and improving product gross margins by divesting non-core business segments[85]. - The company aims to improve operational efficiency by adopting advanced technologies in its production processes[191]. - The company has maintained a stable management team with no significant changes in key personnel[186]. Customer Engagement and Market Trends - User data indicates a 40% increase in customer engagement through digital platforms in 2021[14]. - The company has seen a significant increase in demand for medical devices due to rising healthcare awareness and supportive government policies[28]. - The company organized various online events to strengthen customer engagement, attracting over 600 healthcare professionals to participate in a knowledge competition related to needle stick prevention[68]. - The company is focusing on expanding its R&D capabilities in biotechnology, which is expected to enhance its product offerings[157]. - The overall market outlook for Yangpu Medical remains positive, with expectations of revenue growth driven by new product launches and market expansion efforts[158].

Financial Performance - The company's revenue for Q1 2022 was ¥179,558,042.65, a decrease of 22.12% compared to ¥230,571,623.19 in the same period last year[5] - The net profit attributable to shareholders was -¥37,706,527.24, representing a decline of 213.90% from ¥33,105,576.16 in the previous year[5] - The total comprehensive income attributable to shareholders was -¥37,745,337.58, reflecting a decrease of 213.62% compared to the previous year[13] - The company's sales revenue decreased by 31.08%, amounting to ¥206.72 million compared to ¥299.96 million in the previous period, primarily due to a reduction in the collection of accounts receivable[14] - Total operating revenue for Q1 2022 was CNY 179,558,042.65, a decrease of 22.1% compared to CNY 230,571,623.19 in the same period last year[40] - Net profit for Q1 2022 was a loss of CNY 37,314,648.73, compared to a profit of CNY 33,136,764.38 in Q1 2021[41] - The total comprehensive income attributable to the parent company was -37,745,337.58 CNY, compared to 33,220,091.78 CNY in the previous period[42] Cash Flow and Assets - The net cash flow from operating activities was -¥19,528,640.89, down 152.14% from ¥37,453,519.31 in the same period last year[5] - Cash flow from operating activities showed a significant decline of 152.41%, resulting in a net cash flow of -¥19.53 million, down from ¥37.45 million in the previous period[14] - The company's cash and cash equivalents decreased to CNY 297,924,344.24 from CNY 345,741,475.03 at the beginning of the year, a decline of 13.8%[36] - The ending cash and cash equivalents balance was 294,915,134.55 CNY, compared to 241,803,833.85 CNY in the previous period[46] - The net increase in cash and cash equivalents was -¥46.57 million, a decrease of 261.67% from the previous period's increase of ¥28.81 million[15] - Net cash flow from investing activities was -35,433,912.18 CNY, an improvement from -62,300,026.82 CNY in the previous period[46] Investments and Liabilities - Investment income decreased by 2458.40% to -¥39,719,251.68, primarily due to reduced investment returns from a subsidiary[12] - The total liabilities increased slightly to CNY 795,603,721.94 from CNY 794,625,011.78, an increase of 0.1%[38] - The company repaid bank loans, with cash outflows increasing by 125.52% to ¥93.59 million from ¥41.50 million[15] Shareholder Information - The total number of common shareholders at the end of the reporting period was 35,553[17] - The largest shareholder, 邓冠华, holds 17.55% of the shares, amounting to 54,268,555 shares, with 40,701,416 shares pledged[17] Product Development and Market Position - Subsidiary Guangzhou Yangpu Medical Instrument Co., Ltd. obtained the EU Quality Management System Certificate (MDR), enabling its blood collection needle and microbiological swab products to enter the EU market[22] - The company launched the 20-in-1 mixed sample preservation solution, significantly enhancing the efficiency of large-scale nucleic acid testing during the pandemic[26] - The ImWootton™2030 medical laboratory information management system was introduced, supporting the automation and intelligence transition of medical laboratories[24] Risk Management - The company faces industry policy risks due to high regulatory scrutiny and must adapt to changes in medical reform and regulatory policies[29] - The company is addressing new product and technology development risks by enhancing collaboration with research institutions and accelerating product updates[30] - The company is strengthening management control over subsidiaries to mitigate risks associated with group management and governance[31] - The company is monitoring overseas market risks, particularly in emerging markets, and is using export credit insurance to protect against bad debt losses[32] Operational Efficiency - The company is focused on optimizing internal processes to enhance management efficiency and has implemented a project evaluation system to improve R&D progress[28] - Research and development expenses for Q1 2022 were CNY 9,254,646.08, up 12.6% from CNY 8,219,331.18 in the previous year[41] - The company is implementing measures to retain talent and protect intellectual property, including competitive compensation and equity incentive plans[33] Quality Management - The company maintains a high-standard quality management system that meets ISO9001, ISO13485, and EU regulations, ensuring the continuous provision of safe and effective products[25]

广州阳普医疗科技股份有限公司 2021 年第三季度报告 | 股票代码：300030 | 股票简称：阳普医疗 | 公告编号：2021-071 | | --- | --- | --- | | 债券代码：112522 | 债券简称：17 阳普 S1 | | 广州阳普医疗科技股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人邓冠华、主管会计工作负责人闫红玉及会计机构负责人(会计主管人员)侯全 能声明：保证季度报告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 本报告期比上年同期增 | 年初至报告期末 | 年初至报告期末比上年 | | --- | --- | --- | --- | --- | | | | ...